Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2311 to 2325 of 7685 results

  1. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development [GID-TA10638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development [GID-TA11298] Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472

    Awaiting development [GID-TA11589] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376

    Awaiting development [GID-TA11608] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Seladelpar for previously treated primary biliary cirrhosis ID 6429

    Awaiting development [GID-TA11609] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development [GID-TA11360] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency ID 6466

    Awaiting development [GID-TA11583] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Patritumab deruxtecan for treating EGFR mutation-positive advanced non-small-cell lung cancer after 1 or 2 tyrosine kinase inhibitor treatment ID 6467

    Awaiting development [GID-TA11585] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Venetoclax with azacitidine for treating acute myeloid leukaemia before and after an allogeneic stem cell transplant ID 6468

    Awaiting development [GID-TA11581] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Inebilizumab for treating AQP4-IgG seropositive neuromyelitis optica spectrum disorders ID6430

    Awaiting development [GID-TA11530] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker ID 6469

    Awaiting development [GID-TA11575] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Tiragolumab with atezolizumab for untreated PD-L1-positive advanced non-small-cell lung cancer [ID5122]

    Awaiting development [GID-TA11021] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development [GID-TA10748] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development